Venus Medtech International
Company Details
Status: Public
Employees: 501-1,000
Location:
Kraijenhoffstraat 137, Amsterdam, North Holland 1018RG, NL
Type:
sample
sample
Technology:
sample
sample
About: Venus Medtech is a prominent player in transcatheter technologies for structural heart disease therapies. Our comprehensive solutions treat all four heart valves within the human heart (TAVR, TPVR, TMVR, TTVR) in addition to hypertrophic cardiomyopathy, hypertensive renal denervation therapy.
Founded in 2009 and headquartered in Hangzhou National High-Tech Industrial Development Zone (Binjiang), the company successfully listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2500.HK) in December 2019. Our journey began with the launch of our first product in 2014, under the New Bioprosthetic Aortic Valve Project in China. We followed this with the introduction of the VenusP-Valve in Europe in 2022.
We partner with the top physicians across every continent to understand their challenges and identify opportunities. These insights drive novel breakthrough solutions for a better tomorrow.
We invest more than $200M in R&D every year, operate in more than 650 centers worldwide, hold a portfolio of more than 800 patents, and boast a track record of more than 13,000 real-world implantations.
As a global leader in the making, Venus Medtech's strategic focus is and will always remain to pioneer innovative technology and equip physicians with the tools they need to enhance the quality of life for patients worldwide.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Venus Medtech International | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.